Yamanouchi Seeks Larger U.S. Presence Through Fujisawa Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
The $7.8 bil. deal would ramp up the companies' sales efforts to primary care physicians. In the U.S., Fujisawa details only to the specialty care audience, while Yamanouchi relies on out-licensing agreements.
You may also be interested in...
Yamanouchi Will Promote Vesicare With 150 Specialty Sales Reps
FDA clears Vesicare for the treatment of overactive bladder. Yamanouchi and co-promotion partner GlaxoSmithKline will launch solifenacin in January 2005, with GSK sales reps handling primary care duties and Yamanouchi reps detailing to urologist and ob/gyns.
Yamanouchi Will Promote Vesicare With 150 Specialty Sales Reps
FDA clears Vesicare for the treatment of overactive bladder. Yamanouchi and co-promotion partner GlaxoSmithKline will launch solifenacin in January 2005, with GSK sales reps handling primary care duties and Yamanouchi reps detailing to urologist and ob/gyns.
Japanese Pharma Sea Change: U.S. Development Takes Focus Over Licensing
The traditional pattern of Japanese firms outlicensing their products for the West is shifting as the U.S. market looks increasingly appealing compared to Japan’s price controls and sagging economy. Major Japanese pharmas have been building U.S. development capability, resulting in a full pipeline of products to be developed and marketed directly in the U.S.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: